02
Jan
Mcdermott df, sosman ja, sznol m, et al. Join leading researchers in the field and publish with hindawi.
Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma:
Atezolizumab renal cell carcinoma. A total of 102 patients were enrolled. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (immotion151): This phase ib study (nct03170960.
Mcdermott df, sosman ja, sznol m, et al. Pal sk, mcgregor b, suárez c, et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma:
The latter is a patient population with high unmet medical need and limited participation in clinical trials. Results of a multicenter phase ii study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. The latter is a patient population with high unmet medical need and limited participation in clinical trials.
Atezolizumab has several approved indications in urothelial carcinoma, but none yet in rcc. Ad a forum for urologists, nephrologists & basic scientists working in the field of urology. Join leading researchers in the field and publish with hindawi.
A study of atezolizumab as adjuvant therapy in participants with renal cell carcinoma (rcc) at high risk of developing metastasis following nephrectomy trial. In this multicenter phase ii trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (rcc) with variant histology or any rcc histology with ≥ 20% sarcomatoid differentiation. Updated results of activity and predictive biomarkers from a phase ii study.